Premium
Performance of the 2010 rheumatoid arthritis classification criteria
Author(s) -
Davatchi Fereydoun,
Abari Iraj Salehi,
Soroosh Soosan,
Soroosh Mohsen,
Abdollahi Bahar Sadeghi
Publication year - 2012
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2012.01766.x
Subject(s) - medicine , rheumatoid arthritis , rheumatism , rheumatology , rheumatoid factor , subspecialty , erythrocyte sedimentation rate , physical therapy , pathology
Objectives Rheumatoid arthritis ( RA ) needs early treatment to improve clinical outcome by reducing joint damage, radiographic progression and disability. The aim of this study was to evaluate the 2010 R heumatoid A rthritis C lassification C riteria for its ability to classify RA patients, in their early stages, not exceeding 12 months of disease progression. Methods Rheumatoid arthritis ( RA ) patients were selected from A ugust to D ecember 2010, among those coming for their follow‐up. The inclusion criteria were patients with not more than 12 months of disease progression at their first evaluation. Patients were selected from four rheumatology subspecialty clinics. Results Nine hundred and ninety‐seven patients with a confirmed diagnosis of RA entered the study. The female‐to‐male ratio was 4.3/1.0. Mean age was 46.4 years. Mean disease progression at first visit was 6.3 months. The mean follow‐up of their disease was 5.9 years. The 1987 A merican C ollege of R heumatology ( ACR ) criteria were fulfilled for 74% of patients. The ACR / EULAR ( E uropean L eague A gainst R heumatism) criteria were fulfilled for 69% of patients. Ten percent had involvement of 2–10 large joints, 29% 1–3 small joints, 25% 4–10 small joints and 32% more than 10 joints. Low rheumatoid factor ( RF )/anticytoplasmic antibodies ( ACPA ) were discovered in 30%, high RF / ACPA in 37%; high erythrocyte sedimentation rate/C‐reactive protein in 77%, and duration of 6 weeks or more in 92% of patients. There was no significant difference between men and women. Conclusions The 2010 ACR / EULAR criteria have good performance: sensitivity of 69% in early disease (first year), with the same sensitivity in both genders.